Skip to main content
. Author manuscript; available in PMC: 2019 Jan 11.
Published in final edited form as: MOJ Immunol. 2018 Mar 16;6(2):34–42.

Figure 3.

Figure 3

Mechanisms of Tregs-mediated immunosuppression. Tregs promote tumor progression by (1) inhibition of effector T cell proliferation, lysis of effector T cells through release of granzyme B and perforin, or conversion of CD4+ T cells into Tregs; (2) interactions with DCs through downregulation of CD80/CD86 on DCs or upregulation of indoleamine 2,3-dioxygenase IDO in DCs; (3) inhibition of NK cell function through downregulation of NKG2D on NK cells or direct inhibition of NK proliferation and cytotoxicity.